3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 2
2
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Colorectal Neoplasms
216
Stomach Neoplasms
166
Rectal Neoplasms
146
Pancreatic Neoplasms
81
Colonic Neoplasms
77
Neoplasm Metastasis
67
Esophageal Neoplasms
55
Neoplasms
31
Adenocarcinoma Of Esophagus
29
Cholangiocarcinoma
28
Carcinoma, Hepatocellular
26
Adenocarcinoma
26
Biliary Tract Neoplasms
23
Lymphoma, Large B-Cell, Diffuse
19
Recurrence
17
Carcinoma, Non-Small-Cell Lung
16
Gallbladder Neoplasms
14
Breast Neoplasms
14
Head and Neck Neoplasms
11
Locally Advanced Rectal Cancer
10
Liver Neoplasms
10
Gastrointestinal Neoplasms
10
Esophageal Squamous Cell Carcinoma
9
Peritoneal Neoplasms
8
Ovarian Neoplasms
8
Colorectal Cancer Metastatic
7
Bile Duct Neoplasms
6
Urinary Bladder Neoplasms
5
Lymphoma, Non-Hodgkin
5
Lymphoma, Extranodal NK-T-Cell
5
Interventions
Carboplatin
79
pembrolizumab
64
Paclitaxel
64
Cyclophosphamide
47
Capecitabine
34
Doxorubicin
31
Taxes
28
130-nm albumin-bound paclitaxel
28
Albumin-Bound Paclitaxel
27
Gemcitabine
20
atezolizumab
18
Epirubicin
18
Cisplatin
18
Bevacizumab
18
olaparib
17
sacituzumab govitecan
15
Docetaxel
15
eribulin
14
toripalimab
13
durvalumab
13
camrelizumab
13
Drug Therapy
12
apatinib
9
Trastuzumab
9
Radiotherapy
9
Specimen Handling
8
Magnetic Resonance Spectroscopy
8
Biopsy
8
tislelizumab
7
talazoparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Triple Negative Breast Neoplasms
×
Oxaliplatin
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled
NCT01528826
2012-02-08
NVBOX
Fudan University
Phase 2
Unknown
35 enrolled